TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16643550

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 3 mg (1 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (1 mL saline)
Number of subjects: 24
Study: 12893646

Group type: EXPERIMENTAL
Intervention: Inhalation of 800 microg BUD via Turbuhaler
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inhalation of 750 microg FP via Diskus
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 microg BUD
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 microg fluticasone dipropionate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inhalation of BUD and FP on the same day
Number of subjects: 15
Study: 11083533

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 22

Group type: COMPARATOR
Intervention: CT
Number of subjects: 22
Study: 9177549

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 18
Study: 1552406

Group type: EXPERIMENTAL
Intervention: Depakote Sprinkle capsules
Number of subjects: 12

Group type: COMPARATOR
Intervention: Depakene syrup
Number of subjects: 12
Study: 3927481

Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg 3 times daily
Number of subjects: 40
Study: 29326022

Group type: EXPERIMENTAL
Intervention: rTMS targeting the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study: 27513854

Group type: EXPERIMENTAL
Intervention: 0.4ppm ozone exposure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 40
Study: 24464960

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22706026

Group type: EXPERIMENTAL
Intervention: Trans-triepitopic antibody fusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0
Study: 20331585

Group type: EXPERIMENTAL
Intervention: Lymphocyte immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 18558169

Group type: EXPERIMENTAL
Intervention: Ceftriaxone and metronidazole (CM) - 2 total doses per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin, gentamicin, and clindamycin (AGC) - 11 total doses per day
Number of subjects: 100
Study: 16645456

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Severe postoperative pain (numerical rating score > or = 8)
Number of subjects: 808

Group type: COMPARATOR
Intervention: PONV experience
Number of subjects: 808
Study: 12648269

Group type: EXPERIMENTAL
Intervention: Cerec 1 (group 1)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Cerec 2 (group 2)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Cerec 2 with wall-spacing software (group 3)
Number of subjects: 496
Study: 10757194

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) applied to the calf under 40 mm Hg pressure for 150 minutes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Noncompressed calf
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 70
Study: 8865720

Group type: EXPERIMENTAL
Intervention: Gastric intramucosal pH measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepato-splanchnic oxygen extraction ratio measurement
Number of subjects: 0
Study: 1511147

Group type: EXPERIMENTAL
Intervention: Feedback from the Finnish birth register information package sent to 26 hospitals
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Hospitals receiving feedback
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hospitals not receiving feedback (control group)
Number of subjects: 104
Study: 6151243

Group type: EXPERIMENTAL
Intervention: Trimipramine (various doses)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: 50 mg trimipramine in the evening
Number of subjects: 428
Study: 29283791

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study: 27488003

Group type: EXPERIMENTAL
Intervention: Image guided biopsy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Palpation guided biopsy
Number of subjects: 36
Study: 24088617

Group type: EXPERIMENTAL
Intervention: Weight Management (WM) intervention including education about regular daily weight monitoring and coping skills, with a WM booklet and scheduled telephone visits
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Weight Management (WM) intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 21819548

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV)
Number of subjects: 56
Study: 19874314

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections at the temporal hairline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Botulinum toxin injections at the temporal hairline plus extra injections at each temporal line
Number of subjects: 40
Study: 18037223

Group type: EXPERIMENTAL
Intervention: Epo‐alpha (40,000 IU intravenously each injection, 5 doses within 48 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 18
Study: 15925455

Group type: EXPERIMENTAL
Intervention: 30 Gy extended field plus 10 Gy to bulky disease (Arm A)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: 30 Gy involved field plus 10 Gy to bulky disease (Arm B)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Both Arms A and B
Number of subjects: 1204
Study: 14743569

Group type: EXPERIMENTAL
Intervention: Posterior preperitoneal mesh repair (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anterior tension-free repair (Group II)
Number of subjects: 60
Study: 11069340

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.25 mg with bupivacaine 2.5 mg intrathecally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alfentanil 0.25 mg intrathecally
Number of subjects: 30
Study: 8627434

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg per dose, administered less than 24 hours after birth and again every 24 hours for six doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Indomethacin and Placebo
Number of subjects: 90
Study: 1317373

Group type: EXPERIMENTAL
Intervention: bradykinin (1.88 x 10(‐3) M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: capsaicin (3.28 x 10(‐5) M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 4051254

Group type: EXPERIMENTAL
Intervention: Blood transfusion at a speed of 2 ml/min (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood transfusion at a speed of 5 ml/min (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 20
Study: 30954990

Group type: EXPERIMENTAL
Intervention: JSS formula
Number of subjects: 104

Group type: COMPARATOR
Intervention: Modified Shukla's formula
Number of subjects: 104
Study: 31225739

Group type: EXPERIMENTAL
Intervention: Higher protein pasta (10 g protein/serving)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regular pasta (7 g protein/serving)
Number of subjects: 12

Group type: COMPARATOR
Intervention: White rice
Number of subjects: 12
Study: 27824398

Group type: EXPERIMENTAL
Intervention: Quercetin (1 g daily for 12 weeks)
Number of subjects: 84
Study: 25939586

Group type: EXPERIMENTAL
Intervention: Repeated dietary and lifestyle intervention initiated in infancy
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 457
Study: 23835718

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 1,600/800 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) 400/400 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rituximab-refractory patients
Number of subjects: 40
Study: 22085343

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1500 to 2000 mg per day)
Number of subjects: 3414

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 3414

Group type: EXPERIMENTAL
Intervention: Both groups (niacin and placebo)
Number of subjects: 3414
Study: 19406146

Group type: EXPERIMENTAL
Intervention: Intensive counseling
Number of subjects: 82

Group type: COMPARATOR
Intervention: Short-term counseling
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study: 16126743

Group type: EXPERIMENTAL
Intervention: Group jogging exercise regimen (5 sessions of 50 minutes per week for 8 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group jogging exercise regimen
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual daily activities
Number of subjects: 49
Study: 15042477

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with conventional, new atypical or depot neuroleptics
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Combined treatment with conventional and depot neuroleptics
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Clozapine or combination treatment with conventional and atypical neuroleptics
Number of subjects: 307

Group type: COMPARATOR
Intervention: Conventional, new atypical or depot neuroleptics
Number of subjects: 307
Study: 11755553

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) with 17 beta-estradiol patches plus oral medroxyprogesterone acetate for 12 cycles of 28 days (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcium carbonate (group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy postmenopausal women without uterine leiomyomas treated with the same regimen as group A (group C)
Number of subjects: 70
Study: 9416252

Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block with bupivacaine 0.5% in 1:200,000 epinephrine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Continuous lumbar epidural block with morphine
Number of subjects: 61
Study: 8440099

Group type: EXPERIMENTAL
Intervention: CB0006 (anti-TNF monoclonal antibody) at various doses (0.1 mg/kg, 1.0 mg/kg, 10 mg/kg, or two doses of 1 mg/kg 24 hrs apart)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CB0006 (high dose anti-TNF monoclonal antibody)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard supportive care and antimicrobial therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients in shock at study entry
Number of subjects: 80
Study: 3500735

Group type: EXPERIMENTAL
Intervention: Propofol 2.0‐2.5 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone 4‐5 mg kg‐1
Number of subjects: 60
Study: 29324496

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus plane block with 0.4 mL/kg of 0.375% ropivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study: 27551937

Group type: EXPERIMENTAL
Intervention: Continuous bout (CONT) expending a total of 400 kcal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Accumulated bout (2×200 kcal) to total 400 kcal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous and accumulated bouts
Number of subjects: 10
Study: 25281277

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23587451

Group type: EXPERIMENTAL
Intervention: Exemestane for 4 months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Exemestane for 6 months
Number of subjects: 51
Study: 20723260

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18005140

Group type: EXPERIMENTAL
Intervention: Balloon compression (BC)
Number of subjects: 25
Study: 15803166

Group type: EXPERIMENTAL
Intervention: Transconjunctival needling
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no EB)
Number of subjects: 21
Study: 12663707

Group type: EXPERIMENTAL
Intervention: Interferon alfa-NL (Wellferon) given daily for 5 days every 3 weeks for up to 12 cycles
Number of subjects: 283

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 283
Study: 10872763

Group type: EXPERIMENTAL
Intervention: Postoperative patient‐controlled analgesia and continuous epidural block (group 2)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: One‐shot epidural analgesia, postoperative patient‐controlled analgesia, and continuous epidural block (group 3)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 109
Study: 8653161

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine without epinephrine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (administered 3.5 hours before procedure)
Number of subjects: 41
Study: 1521715

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sulglycotide
Number of subjects: 9
Study: 7041623

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (N‐CPAP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oxygen by hood (Control)
Number of subjects: 18
Study: 30730860

Group type: COMPARATOR
Intervention: Rectal indomethacin alone
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Combination of rectal indomethacin and topical spray of epinephrine
Number of subjects: 960
Study: 29034576

Group type: EXPERIMENTAL
Intervention: 5-g curcumin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26627366

Group type: EXPERIMENTAL
Intervention: Clonazepam plus levetiracetam (2.5 g)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Clonazepam plus placebo
Number of subjects: 203
Study: 24930819

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (daily practice during Asian history course)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Active control (African history course with matched experiential activity)
Number of subjects: 101
Study: 18165936

Group type: EXPERIMENTAL
Intervention: Methylcellulose pills (2-week supply), told it was a cognitive enhancer
Number of subjects: 40

Group type: COMPARATOR
Intervention: No pills (control group)
Number of subjects: 40
Study: 15369494

Group type: EXPERIMENTAL
Intervention: Systematic relaxation for 15 minutes during recovery from the first ambulation after surgery
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no systematic relaxation)
Number of subjects: 102
Study: 11695508

Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: High salt diet
Number of subjects: 15
Study: 9394942

Group type: EXPERIMENTAL
Intervention: Naltrexone, 1.0 mg/kg, daily
Number of subjects: 24
Study: 8205270

Group type: EXPERIMENTAL
Intervention: Fasting serum insulin
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fasting serum insulin in Apo E 3/2 individuals
Number of subjects: 622

Group type: COMPARATOR
Intervention: Fasting serum insulin overall
Number of subjects: 622
Study: 3111292

Group type: EXPERIMENTAL
Intervention: Ro15-1788 (Anexate)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 28
Study: 11495173

Group type: EXPERIMENTAL
Intervention: Weight control plus cognitive behavioral body image therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Weight control
Number of subjects: 65
Study: 31560382

Group type: EXPERIMENTAL
Intervention: 7.1 to 14.0 drinks per week
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: More than 14.0 drinks per week
Number of subjects: 3021

Group type: EXPERIMENTAL
Intervention: Daily low-quantity drinking
Number of subjects: 3021

Group type: COMPARATOR
Intervention: Complete abstention
Number of subjects: 3021
Study: 30600956

Group type: EXPERIMENTAL
Intervention: Antihistamines and atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antihistamines and placebo
Number of subjects: 40
Study: 26964644

Group type: EXPERIMENTAL
Intervention: 10 min aerobic exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 30 min aerobic exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 min resistance exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 30 min resistance exercise
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 31
Study: 25350130

Group type: EXPERIMENTAL
Intervention: TFV 1% gel (40 mg TFV per 4 ml gel application)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral TDF (300 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hydroxyethyl‐cellulose (HEC) placebo gel
Number of subjects: 18
Study: 22035157

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Etanercept 50 mg weekly (QW)
Number of subjects: 752
Study: 20375380

Group type: EXPERIMENTAL
Intervention: 2D processed volumes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3D processed volumes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Original volumes
Number of subjects: 80
Study: 17602126

Group type: EXPERIMENTAL
Intervention: Injectable heroin
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 1015
Study: 16195039

Group type: EXPERIMENTAL
Intervention: Coloured volleyballs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plain white volleyballs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Different colour combinations of volleyballs
Number of subjects: 20
Study: 12366624

Group type: EXPERIMENTAL
Intervention: Preoperative supraphysiological testosterone (600 mg T enanthate intramuscularly weekly for 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (sesame oil)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preoperative supraphysiological testosterone
Number of subjects: 25
Study: 10404843

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 to 40 mg)
Number of subjects: 2856

Group type: COMPARATOR
Intervention: Simvastatin (10 to 40 mg)
Number of subjects: 2856
Study: 7606078

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study: 2119796

Group type: EXPERIMENTAL
Intervention: Preoperative administration of fenbufen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7318331

Group type: EXPERIMENTAL
Intervention: Reduction of about 70% in salt intake for 24 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no change in salt intake
Number of subjects: 0
Study: 30367938

Group type: EXPERIMENTAL
Intervention: Dexamethasone insert
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 29251360

Group type: EXPERIMENTAL
Intervention: Therapeutic INR on warfarin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Subtherapeutic INR on warfarin
Number of subjects: 3

Group type: COMPARATOR
Intervention: No anticoagulants
Number of subjects: 3
Study: 26319650

Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS (Frequency: 8Hz, pulse duration: 250µs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Self-applied TENS (Frequency: 85Hz, pulse duration: 75µs)
Number of subjects: 22
Study: 23866673

Group type: EXPERIMENTAL
Intervention: Standard imaging modalities (SPECT)
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Advanced imaging modalities (CMR or PET)
Number of subjects: 1261
Study: 23025261

Group type: EXPERIMENTAL
Intervention: Explaining the relevance of activities
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Providing choice from PA options selected by the teacher
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Providing equipment and free choice of activities
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 16
Study: 20019425

Group type: EXPERIMENTAL
Intervention: Tetric Flow
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Grandio Flow
Number of subjects: 105

Group type: COMPARATOR
Intervention: Transbond XT adhesive
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: X-flow
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Filtek Z350 flow
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Admira Flow
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aelite Flow
Number of subjects: 105
Study: 17519410

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: All study regimens
Number of subjects: 601
Study: 15286095

Group type: EXPERIMENTAL
Intervention: BIA 2-093 (200 mg bid)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BIA 2-093 (400 mg qd)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BIA 2-093 (800 mg qd)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BIA 2-093 (1200 mg qd)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11380088

Group type: EXPERIMENTAL
Intervention: Closed mitral commissurotomy (CMC)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Percutaneous mitral balloon valvuloplasty (PMBV)
Number of subjects: 580
Study: 9672931

Group type: EXPERIMENTAL
Intervention: ondansetron 100 micrograms.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ondansetron 50 micrograms.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: droperidol 60 micrograms.kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline control
Number of subjects: 80
Study: 8030593

Group type: EXPERIMENTAL
Intervention: Resistance training with a diet providing 0.8 g protein.kg‐1.d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance training with a diet providing 1.6 g protein.kg‐1.d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 12